Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Page 22 on presentation is Charpentier.
Long here... but how high do you think we’re going this time?
I’m taking the green pill Dragon!
Did you buy any warrants? Depending on the next few months, my plan is to keep my stock in for the long term... but I bought a few warrants that are expendable the first sign of insider selling next time! I don’t know if it’s a good strategy or not... but helps me sleep a little better ;)
Certainly will!
Being Bogarts’ hand-puppet doesn’t look much better than the trolling imo.
Adams taking part in the financing wasn’t enough of a faith builder either, does everyone forget how much he made in the 2+ range? He’s just trading the stock, which doesn’t help us long holders either. Is he just interested in trading the stock?...or does he believe in the long term?
It’s an impressive team on paper, that’s what sucked me in. There is such great potential here, but biosynthesis better start producing some gains to justify not commencing trials.
Eli Lilly has a strong history with cannabinoids and they’ve been doing a lot of deals and throwing a ton of cash around, especially in the “pain” department. IN have two guys on the inside track there. Makes me wonder why Eli Lilly doesn’t seem interested?
The closest to news was that hideous “pump” piece that keeps being posted and reposted on another board. Other companies are out there working and making deals, yet IN doesn’t seem interested in keeping shareholders up-to-date. I’m bored and a little concerned with the antics at this point. Time to go to the beach and wish for something from this company other than empty promises and no sign of trials ever commencing!
I agree. Would like to see some positive as far as moving Biosynthesis ahead rather than the constant push-back of trials we’ve been seeing since even before Adams came aboard. I just hope all this talk of “rescheduling” isn’t just a sign that they’ve had no luck in gearing up production until they can produce in the US. I would think that would just be icing on the cake, and production will start in another friendly country.
At least the stock has some signs of support now.
Keep your hope strong, hopefully we’ll be out of the dark soon:)
The need for Inmed product couldn’t be greater.
Statement from FDA warning about significant health risks of contaminated illegal synthetic cannabinoid products that are being encountered by FDA:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm614027.htm?utm_campaign=07192018_Statement_FDA%20warns%20of%20significant%20health%20risks%20from%20synthetic%20cannabinoids&utm_medium=email&utm_source=Eloqua
Thank you for sharing!
Thanks HorizonBull :)
Chris Bogart and Craig Schneider, founders of Inmed do own less than 10% each now but still share same office space from what I understand, and still collect a cheque for being advisors. So technically no longer “insiders”?
This company will soar on it’s own merits, I just want to see it being ran with a little more integrity.
Thanks for the information!
Somebody connected to them made the call, and author claims he talked to Adams. Notice one of the testimonials belonged to “Chris B.”?
Honestly, even if another “pump” in action. I’m hanging on to most my shares. Potential is too big for this company.
Correction : breast cancer used to be on their pipeline, going from memory but can’t support from their website anymore
Really?!! Let’s start with our Mystery Man and supporting charts.
Craig Schneider:
Choom
Corex Gold
Inmed
Eric Adams - CEO - formerly with QLT
Ado Muhammed - GW
Pipeline includes Breast Cancer
Oh... and biosynthesis
Please subscribe and prove me wrong ;)
https://www.angelnexus.com/o/web/165728
Just saw this published on another board. Kinda makes me embarrassed to own this stock. I just hope not another “pump” followed by no real news like December.
Hopefully Inmed has a follow up to this. Couldn’t be a better time to draw attention to themselves.
Haha! I’ll gladly give you a penny a share!
I took a look at the FB page, and yes!...Very misleading. If this is a typo on their part I think they would be a little more timely in correcting their “clinical trials” statement. Unless the company wants to mislead new investors... or better it is actually true and perhaps they have a partnership??
July 4, 2019. Surely investors will do well with these warrants, as I’m sure Inmed will be well over $5 by then. That’s why I don’t really see the incentive for these options not flooding the market when trade able. The pp was equal warrants to options.
Anyone looking for a buying opportunity looks for these points with any company. I’ve watched stocks get hammered for just a penny gain and then quickly rebound after the shares are done. I have some extra money put away just for this. Why buy now?... if you can get it on sale in a few weeks? I already own enough at a low enough price, so if I don’t get any shares on sale... it’s no big deal. Lots of other stocks out there I have my eye on. This is still my favourite company with the best potential. Maybe a non-issue for you... but an opportunity for some! So I agree to disagree with you ;)
The warrants are @ 1.25 with a 18 month expiry. Normally options are free trading after a 4 month hold... at least that’s what I’ve been told by industry friends.
If share price does take a tumble on these options, I’ll be more than happy to improve my position as I’m sure a few others will do likewise.
Well, if something significant doesn’t come out for news from the company... we could take a bit of a kicking until these shares are bled out. Hopefully Blacher has the connections to get some interest. Remember these options were done when the company was trading at a much higher price. Option holders are expecting some kind of return, or they won’t be in hurry to exercise those warrants.
Don’t we have 13.5 million options @ .70 flooding the market early May?
Welcome to club “Inmed”! Can’t answer your questions... but stock seems to trade evenly across all 3 boards (MWG2.F).
Until the company confirms.... purely all speculation! But I love this little “hobby” ;)
Did you notice another new name listed as an employee? Eric Hsu had 450k options issued. I did a little online lurking and found this profile that might be a potential fit...
https://ca.linkedin.com/in/eric-hsu-655a635
https://www.bloomberg.com/research/stocks/private/person.asp?personId=224791979&privcapId=9516520&%2520Inc.
Did you notice how many shares are proposed to Josh Blacher? Gotta be worth a little belief in the future to get in 1.25m @ $1.55!
Proposed stock options:
https://webfiles.thecse.com/CNSX_Form_11_-_Notice_of_Proposed_Stock_Option_16.pdf?OoDexCY8M8HDxQ4Slz_GdZyAQuVJLl6A
Looks like a good sign folks! Don’t think we’ll being travelling much lower than this bench mark price in the future. Cheers
Lol... feeling “stinky” but not in the right way Tauby! What the “Cat” happened here today? Guess we have to close our eyes again! What a volatile investment.
One of the main ingredients in the Glaucoma formula is Hylauronic acid... which is something as a skin care formulator I am very familiar with. Kudos for taking a natural approach with an ingredient the body can process with ease (and already there). Hyaluronic acid is a humectant that attracts moisture, in skincare it’s a no-brainer... such as using for an eye care formula that these guys figured out.
That’s only the most recent information I could find on him. He was hired by Inmed as a consultant Feb. Maybe do both?
I found this on the CSE monthly report for Inmed:
“The Company entered into a Consulting Agreement with Josh Blacher a non-related person, to provide services for Corporate Development and Investor Relations.”
This is what I found on him: (could be wrong though... might be just a guy they pulled off the street for advice ;)
Mr. Blacher joins Therapix with ten years of experience in senior financial and business development related positions at publicly-traded biotechnology and pharmaceutical companies, as well as 14 years in capital markets in the United States. Prior to joining Therapix, Mr. Blacher served as Chief Financial Officer at Galmed Pharmaceuticals (GLMD). Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.
"Now that Therapix has completed its U.S. IPO and NASDAQ listing, and initiated additional clinical trials, it is clear that we will need someone of Josh's caliber to help us develop and bring awareness of our growth strategy to the U.S. capital markets, as well as monetize our assets globally. We're confident that Josh's broad-based experience and track record will help us accomplish our objectives," commented Dr. Elran Haber, Therapix's Chief Executive Officer and Dr. Ascher Shmulewitz, the Company's Executive Chairman. Drs. Haber and Shmulewitz continued, "We're delighted to welcome Josh to the company."
So what does everyone make of the new consultant Josh Blacher? A highly experienced CFO with initial research...
Yes... I feel like a hero to instant zero in a heartbeat with this company. Been here for a long time but can honestly say my stomach is having a really hard time with this latest drop. Inmed overall has been kicked more than the average pot stocks... and they’re a pharma company!
I thought Eric Adams was the answer to making this company clean and accountable... the latest actions have me thinking otherwise. Funny how the paid pumps have completely disappeared and the company knew to sell at the top and leave the rest of us long term shmucks holding the bag.
Thanks for glossy print over the holidays.... should’ve included a card that mentioned to sell cause we are!!!
Still believe in what this company has overall, but very dissatisfied with the lack of support.
https://www.inmedpharma.com/investors/presentation/
Link to their website, new investor presentation is up
Also check their CSE listing
http://thecse.com/en/listings/life-sciences/inmed-pharmaceuticals-inc